Advances in technology have led to an increase in the number of business models being employed by biotechnology companies in Europe. But not all of these models will survive, according to Valérie Sabatier of the University of Grenoble.
Advances in technology have led to an increase in the number of business models being employed by biotechnology companies in Europe. But not all of these models will survive, according to Valérie Sabatier of the University of Grenoble.